Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 17/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4542366 | 0.75 | NR3C2 (0.59) | NR3C2MAPK14 | |
| SCHEMBL4542115 | 0.74 | NR3C2 (1.00) | NR3C2MAPK14MAPK1GSK3B | |
| SCHEMBL4540895 | 0.74 | NR3C2 (0.91) | NR3C2MAPK14MAPK1GSK3B | |
| SCHEMBL6127541 | 0.73 | NR3C2 (1.00) | NR3C2 | |
| SCHEMBL3829682 | 0.73 | NR3C2 (0.57) | NR3C2GSK3B | |
| SCHEMBL6127596 | 0.73 | NR3C2 (0.64) | NR3C2 | |
| SCHEMBL4559774 | 0.72 | NR3C2 (1.00) | NR3C2MAPK14GSK3B | |
| SCHEMBL4537652 | 0.72 | NR3C2 (1.00) | NR3C2MAPK14GSK3B | |
| SCHEMBL4542773 | 0.72 | MAPK14 (0.57) | NR3C2MAPK14 | |
| SCHEMBL4539921 | 0.72 | NR3C2 (1.00) | NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| US-8722709-B2 | Mineralocorticoid receptor antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-05-13 | — | — | US | disclosed |
| EP-2638012-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2013-09-18 | — | — | EP | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2012-11-15 | — | — | US | disclosed |
| WO-2012064631-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012064631-A1 | PYRIDYL UREAS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289551-A1 | MINERALOCORTICOID RECEPTOR ANTAGONISTS | NR3C2, MC2R, AVPR2 | NR3C2 1/4885MAPK14 1484/4885MAPK1 1712/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.